Overview

Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With HRD-positive Recurrent Platinum-resistant Ovarian Cancer.

Status:
Not yet recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This is a single-arm, exploratory study. People with HRD-positive recurrent platinum-resistant ovarian cancer who have not received any previous systemic antitumor therapy for esophageal cancer were selected to evaluate the efficacy and safety of adebrelimab combined with fuzuloparib.
Phase:
Phase 2
Details
Lead Sponsor:
Fujian Cancer Hospital